@article {Williams315, author = {Williams, Hywel D. and Trevaskis, Natalie L. and Charman, Susan A. and Shanker, Ravi M. and Charman, William N. and Pouton, Colin W. and Porter, Christopher J. H.}, editor = {Christopoulos, Arthur}, title = {Strategies to Address Low Drug Solubility in Discovery and Development}, volume = {65}, number = {1}, pages = {315--499}, year = {2013}, doi = {10.1124/pr.112.005660}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Drugs with low water solubility are predisposed to low and variable oral bioavailability and, therefore, to variability in clinical response. Despite significant efforts to {\textquotedblleft}design in{\textquotedblright} acceptable developability properties (including aqueous solubility) during lead optimization, approximately 40\% of currently marketed compounds and most current drug development candidates remain poorly water-soluble. The fact that so many drug candidates of this type are advanced into development and clinical assessment is testament to an increasingly sophisticated understanding of the approaches that can be taken to promote apparent solubility in the gastrointestinal tract and to support drug exposure after oral administration. Here we provide a detailed commentary on the major challenges to the progression of a poorly water-soluble lead or development candidate and review the approaches and strategies that can be taken to facilitate compound progression. In particular, we address the fundamental principles that underpin the use of strategies, including pH adjustment and salt-form selection, polymorphs, cocrystals, cosolvents, surfactants, cyclodextrins, particle size reduction, amorphous solid dispersions, and lipid-based formulations. In each case, the theoretical basis for utility is described along with a detailed review of recent advances in the field. The article provides an integrated and contemporary discussion of current approaches to solubility and dissolution enhancement but has been deliberately structured as a series of stand-alone sections to allow also directed access to a specific technology (e.g., solid dispersions, lipid-based formulations, or salt forms) where required.}, issn = {0031-6997}, URL = {http://pharmrev.aspetjournals.org/content/65/1/315}, eprint = {http://pharmrev.aspetjournals.org/content/65/1/315.full.pdf}, journal = {Pharmacological Reviews} }